GENEVA, Switzerland, April 4, 2019 /PRNewswire-PRWeb/ -- Today, Ipsen and Servier, two global biopharmaceutical companies,
NCDs are responsible for 71 percent of global deaths annually and 15 million people who die from an NCD are between the ages of 30 and 69 years. An alarming 85 percent of these premature deaths occur in LMICs (World Health Organization). Health systems in LMICs are often not optimised to address this growing burden and people face multiple barriers to prevention, treatment and care.
Now consisting of more than 25 biopharmaceutical companies, Access Accelerated unites industry action and applies member companies' global reach and local expertise to address the NCD burden. By working with partners to co-create scalable and sustainable solutions, the initiative supports inclusive local and country-led engagement and ownership. Both Servier and Ipsen have embraced the Access Accelerated commitment to achieve the United Nations Sustainable Development Goals (SDGs), particularly, target 3.4 to reduce premature deaths from NCDs by one-third by 2030.
Ipsen, based in Paris, France, aims to improve lives through innovative medicines in oncology, neuroscience and rare diseases. Ipsen sells more than 20 medicines in 115 countries and has over 5,700 employees worldwide.
"Knowing that patients don't have time to wait, Ipsen is delighted to team up with Access Accelerated. To benefit patients around the world, we'll leverage our legacy and strong expertise to support better access to treatment and care," said Dominique Laymand, Ipsen's Executive Vice President, Ethics and Social Responsibility Chief Officer.
Servier is an international pharmaceutical company headquartered in France, committed to providing accessible quality healthcare to patients. Operating in 149 countries, Servier is focused on five major areas: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes.
"Servier is dedicated to therapeutic progress to serve patient needs. We have a social responsibility to improve access to health for patients. Servier's participation in Access Accelerated will support this everyday commitment," said Vincent Minvielle, Head of Servier Corporate Social Responsibility.
Access Accelerated Director James Pfitzer said, "Servier and Ipsen bring a wealth of knowledge and expertise in NCD care and we are delighted for both companies to join Access Accelerated. Their contributions will further bolster our efforts to combat the global NCD crisis and end premature deaths from preventable, treatable diseases."
About Access Accelerated Access Accelerated is a global partnership of more than 25 biopharmaceutical companies aimed at addressing the growing NCD health challenge. Using a multi-sectoral approach, Access Accelerated develops, measures and replicates sustainable programs in low- and middle income countries to advance access to NCD prevention and care. For more information about Access Accelerated visit: https://accessaccelerated.org/
About Ipsen Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over 2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. For more information on Ipsen, visit: http://www.ipsen.com.
About Servier Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, cancer and metabolism, immune-inflammatory and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. For more information on Servier, visit: https://servier.com
SOURCE Access Accelerated
Subscribe to our Free Newsletters!